stockrow
Friday 6 November 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.55
0.16
−9.36%
Follow XTLB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.67 | — | +0.7 pt | ||||||
| EBT | (3) | (1) | 3 | (1) | (3) | 0 | (1) | (2) | 0 | (1) | (12.6%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (3) | (1) | 3 | (1) | (3) | 0 | (1) | (2) | (1) | (7) | +11.8% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (3.60) | (0.68) | 2.40 | (1.05) | (2.30) | 0.32 | (0.99) | (1.32) | (0.61) | (3.11) | (1.6%) | ||||||
| Cash flow | (2.53) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.96) | (0.46) | (17.3%) | ||||||
| Capex | (0.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | (2.62) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.99) | (0.46) | (17.6%) | ||||||
| Book value | 3.92 | 3.08 | 6.47 | 5.43 | 2.81 | 4.01 | 2.94 | 1.63 | 3.23 | (0.11) | n/m | ||||||
| Shares, m | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | +14.1% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | 5.63 | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | 1.93 | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 4.84 | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (2.56) | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (2) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (1) | (5.7%) | |||||
| Capex | 0 | 0 | — | 0 | 0 | — | — | — | 0 | — | (2.5%) | ||||||
| Free cash flow | (2) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (1) | (6.1%) | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 2 | 6 | 8 | 7 | 6 | 6 | 4 | 2 | (1) | 0 | n/m | |||||
| Net debt | (2) | (4) | (8) | (7) | (6) | (6) | (4) | (2) | (1) | 0 | n/m | ||||||
| Shareholders’ equity | 3 | 4 | 8 | 7 | 4 | 5 | 4 | 2 | 5 | 0 | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (61.03) | (16.27) | 39.39 | (17.06) | (43.08) | 6.63 | (24.95) | (53.90) | (18.71) | (159.91) | (98.9) pt | |||||
| ROIC | (630.17) | (2,433.59) | (247.81) | (208.83) | 0.00 | 0.00 | (197.84) | (223.42) | (10.93) | 0.00 | +630.2 pt | ||||||
| ROE | (67.20) | (24.77) | 50.01 | (17.61) | (55.78) | 9.73 | (28.89) | (57.31) | (26.83) | (269.02) | (201.8) pt | ||||||
| People | |||||||||||||||||
| People | Employees | 7 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | (9.0%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2012 · latest quarter Sep 2014 · fundamentals updated 26 Oct 2026
XTL Biopharmaceuticals Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TPST Tempest Therapeutics, Inc. | $7.5M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALZN Alzamend Neuro, Inc. | $7.5M | — (loss-making) | — | — | n/m | +51.82% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | $7.5M | — (loss-making) | — (loss-making) | −39.66% (below 0%: shrinking) | n/m | +5.08% (above 0%: growing) | (422.22%) | (2,437.96%) | Compare |
| VTGN VistaGen Therapeutics, Inc. | $7.3M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| SNGX Soligenix Inc. | $7.3M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $7.3M | — (loss-making) | — | −39.32% (below 0%: shrinking) | 0.00% | +46.78% (above 0%: growing) | 0.00% | 0.00% | |
| MTVA MetaVia Inc. | $7.2M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $7.0M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $7.3M | — | — | −39.66% | — | +32.67% | 0.00% | 0.00% |